Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Runimotamab - Genentech

Next Previous
Drug Profile

Runimotamab - Genentech

Alternative Names: BTRC-4017A; HER2/CD3 TDB; RG-6194; RO-7227780

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Solid tumours

Most Recent Events

  • 03 Jan 2024 Runimotamab is still in phase I trials for Breast cancer, Gastric cancer and Solid tumors (Late-stage disease, Metastatic disease, Second-line-therapy or greater) in Spain, South Korea, Japan, Italy, France, Denmark, Canada, Belgium, Australia, USA (IV, Infusion) (Roche Genentech Pipeline, January 2024)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark, Canada, Belgium, USA, Spain, South Korea, Japan, Italy, France (IV, Infusion)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Gastric-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA, Australia, Belgium, Canada, Denmark, France, Italy, Japan, South Korea, Spain (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top